|POZEN Reports Fourth Quarter and Full-Year 2004 Results|
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 18, 2005--POZEN Inc. (NASDAQ: POZN), announced today it will host a conference call following the release of financial results for the fourth quarter and full-year 2004. The company will release results before the market opens on Monday, February 28, 2005. John R. Plachetka, Pharm.D., POZEN's chairman, president and chief executive officer, and William L. Hodges, chief financial officer, will host the conference call the same day at 11:00 a.m. Eastern Time.
The conference call will be simulcast live on the Internet, and can be accessed by logging on to www.pozen.com. A replay will be available for seven days in the Investor Relations section of the company's website. POZEN's fourth quarter and full-year results release can be accessed in the News section at www.pozen.com.
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. POZEN is also exploring the development of product candidates in other pain-related therapeutic areas. POZEN has development and commercial alliances with GlaxoSmithKline, Xcel Pharmaceuticals, and Nycomed. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN." For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc. Bill Hodges 919-913-1030 or Fran Barsky 919-913-1044
SOURCE: POZEN Inc.